I-016 Giammarco Baiardi
population pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation
Wednesday 10:20-11:50 |
I-045 Nils Bundgaard
Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)
Wednesday 10:20-11:50 |
I-046 Andrew Butler
Predicting the effect of postpartum changes in breastmilk composition on the partitioning of anti-malarial medications
Wednesday 10:20-11:50 |
I-070 Craig Comisar
Population pharmacokinetic modeling to support dose selection of zavegepant nasal spray in pediatrics.
Wednesday 10:20-11:50 |
I-075 Liu Dan
Population pharmacokinetics modeling of selpercatinib and simulation to support posology in paediatric and adolescent patients
Wednesday 10:20-11:50 |
I-086 Laure Deyme
Population pharmacokinetic analysis of eliglustat in pediatric patients with Gaucher disease
Wednesday 10:20-11:50 |
I-115 Gastón García Orueta
Population pharmacokinetics of teicoplanin in critically ill children undergoing continuous kindey replacement therapy
Wednesday 10:20-11:50 |
II-012 Katharina Martha Götz
The dose-response relationship of rituximab in pediatric patients after allogeneic hematopoietic stem cell transplantation – Model-informed evidence generation for a real-world problem
Wednesday 15:20-16:50 |
II-022 Andrea Guzmán
Potential of Tacrolimus CYP3A5 genotyping to predict phenotype (C0/Dose/Weight ratio) and applicability of PBPK modelling to improve dosing strategies in paediatric kidney transplant recipients
Wednesday 15:20-16:50 |
II-030 Huan He
Is the model predictive performance with von Willebrand factor superior to others? An external evaluation of population pharmacokinetic models for FVIII concentrate BAY 81-8973 in pediatric patients with haemophilia A
Wednesday 15:20-16:50 |
II-091 Sebastiano Lava
Study design optimization in paediatric rare diseases: a case study on empagliflozin in paediatric heart failure
Wednesday 15:20-16:50 |
II-108 CHENYAO LIU
Population Pharmacokinetic of ketamine and norketamine in pediatric subjects during analgosedation
Wednesday 15:20-16:50 |
III-018 Andres Mazariegos Herrera
Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa
Thursday 09:50-11:20 |
III-057 Zinnia Parra-Guillen
Optimal study design for pharmacokinetic modeling of teicoplanin in critically ill children, including those undergoing Continuous Renal Replacement Therapy
Thursday 09:50-11:20 |
III-077 Laure-Hélène Préta
Antidepressants transplacental transfer modeling using ex vivo perfusion of isolated human placenta cotyledon
Thursday 09:50-11:20 |
IV-001 Gianluca Selvaggio
Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children
Thursday 15:00-16:30 |
IV-046 Lufina Tsirizani
Population pharmacokinetics of ritonavir administered to boost lopinavir, atazanavir, or darunavir in children with HIV in Africa.
Thursday 15:00-16:30 |
IV-055 Jennie van Dyk
Oral amoxicillin/clavulanate in paediatric patients with severe community acquired pneumonia: a popPK analysis from the PediCAP trial
Thursday 15:00-16:30 |
IV-059 Anne van Rongen
The impact of being born Small for Gestational Age (SGA) on the clearance of vancomycin versus morphine and midazolam
Thursday 15:00-16:30 |
IV-093 Jen-Hao (Eric) Wu
Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098)
Thursday 15:00-16:30 |
IV-095 Maria Xiberras
External Validation of a Population Pharmacokinetic Model for Morphine and its Metabolites in Children under 3 Years who Underwent Cardiothoracic Surgery
Thursday 15:00-16:30 |
IV-111 Qiaolin Zhao
Population pharmacokinetic analysis for pediatric patients with inflammatory bowel disease receiving infliximab
Thursday 15:00-16:30 |
IV-115 Yuanxi Zou
Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis
Thursday 15:00-16:30 |
